You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for KML 29
KML 29 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor. Exhibits potent inhibition of human, mouse and rat MAGL (IC50 values are 5.9, 15 and 43 nM, respectively). Exhibits no detectable inhibition of FAAH (IC50 > 50000 nM). Potently and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50 = 2.5 nM and >50 μM for 2-AG and AEA respectively).
Sold under license from The Scripps Research Institute
Compound Libraries for KML 29
Technical Data for KML 29
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for KML 29
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for KML 29
The following data is based on the product molecular weight 549.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.82 mL||9.1 mL||18.2 mL|
|5 mM||0.36 mL||1.82 mL||3.64 mL|
|10 mM||0.18 mL||0.91 mL||1.82 mL|
|50 mM||0.04 mL||0.18 mL||0.36 mL|
References for KML 29
References are publications that support the biological activity of the product.
Ueda et al (2012) Discrimination between two endocannabinoids. Chem.Biol. 19 545 PMID: 22633404
Chang et al (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem.Biol. 19 579 PMID: 22542104
If you know of a relevant reference for KML 29, please let us know.
View Related Products by Product Action
Keywords: KML 29, KML 29 supplier, KML29, MAGL, inhibitor, MAG, lipase, monoacylglycerol, inhibitors, MGL, endocannabinoids, 2, AG, arachidonoylethanolamide, anandamide, inhibits, 4872, Tocris Bioscience
2 Citations for KML 29
Citations are publications that use Tocris products. Selected citations for KML 29 include:
Margaret M et al (2019) Microglial Phagocytosis of Newborn Cells Is Induced by Endocannabinoids and Sculpts Sex Differences in Juvenile Rat Social Play. Neuron 102 435-449.e6 PMID: 30827729
Morena et al (2016) Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. Neuropharmacology 111 59 PMID: 27553121
Do you know of a great paper that uses KML 29 from Tocris? Please let us know.
Reviews for KML 29
There are currently no reviews for this product. Be the first to review KML 29 and earn rewards!
Have you used KML 29?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.